Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Focal

This article was originally published in The Gray Sheet

Executive Summary

Focal: Inks collaborative product development agreement with Chiron and Ciba Pharmaceuticals under which Chiron and Ciba restenosis drug candidates will be combined with Focal's development-stage biodegradable gel drug delivery technology. Focal says the agreement will provide "research funding, milestone fees and future royalty payments on product sales." Focal's light-activated, adhering gel is designed to be deposited locally via a fiber-optic, double-balloon catheter that is under development. After placement, the drug combined with the gel would slowly release as the gel degrades, Focal explains...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT006092

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel